Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Chronic Ailments Increases Demand for Transplantations
4.2.2 Technological Advancements in Tissue Engineering and Organ Transplantations
4.3 Market Restraints
4.3.1 High Cost of Transplantation
4.3.2 Low Availability of Organs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Calcineurin Inhibitors
5.1.2 Antiproliferative Agents
5.1.3 mTOR Inhibitor
5.1.4 Steroids
5.1.5 Others Drug Class
5.2 By Transplant Type
5.2.1 Heart
5.2.2 Kidney
5.2.3 Liver
5.2.4 Lung
5.2.5 Pancreas
5.2.6 Other Transplant Type
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma, Inc
6.1.2 Sanofi (Genzyme)
6.1.3 Bristol-Myers Squibb Company
6.1.4 Novartis AG
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 GlaxoSmithKline Plc
6.1.7 Accord Healthcare Ltd
6.1.8 Mylan Laboratories, Inc
6.1.9 Dr. Reddy’s Laboratories Ltd
6.1.10 Veloxis Pharmaceuticals A/S


7 MARKET OPPORTUNITIES AND FUTURE TRENDS